Angelini
Angelini is a privately owned Italian industrial group whose international activities center on pharmaceuticals, healthcare, technology, beauty and wine.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Angelini is a privately owned Italian industrial group with roots in a pharmaceutical business established by Francesco Angelini in 1919. The group has remained controlled by the Angelini family while developing from its original medicines activity into a broader international portfolio spanning pharmaceuticals, consumer health, personal care, technology, beauty and wine. Its corporate identity was reorganized and presented under the Angelini Industries name in 2022. Pharmaceuticals remain the group’s principal area of activity. Angelini Pharma has been associated with prescription and consumer medicines and with research-driven healthcare products. One of the group’s notable scientific contributions was the development of trazodone, an antidepressant created by Angelini scientists during the 1960s. The group also became associated with Amuchina, a sanitizing solution invented by Oronzio De Nora and produced by Angelini since 2000. In 2020, Angelini acquired ownership of ThermaCare, a transdermal analgesic patch business that Pfizer had separated following the merger of its consumer-health operations with GlaxoSmithKline’s consumer-health division. In January 2021, Angelini acquired Swiss biotechnology company Arvelle Therapeutics for a reported $960 million, strengthening its position in specialty pharmaceuticals and central nervous system treatments. The 2022 rebrand organized the group’s activities under several named businesses: Angelini Pharma, Angelini Technologies, Angelini Wines & Estates, Angelini Beauty and Angelini Ventures. This structure reflects a group model rather than a single mass-market product brand. Alongside healthcare, the portfolio includes industrial and technology activities, wine estates, beauty products and investment activity. The group operates internationally, with offices in 21 countries and approximately 5,800 employees according to the referenced Wikipedia material. Angelini remains a family-owned enterprise rather than a publicly traded corporation. The group is associated with Sergio Marullo di Condojanni and Thea Paola Angelini, who are identified in the reference material as its current leaders. In a 2018 corporate-reputation assessment by the Reputation Institute, Angelini ranked 66th overall and second among life-sciences companies. Because the available reference material gives limited detail on individual subsidiaries, revenue, geographic sales, ownership percentages and the complete current product catalog, those areas are not expanded beyond the documented group-level information.
History
Angelini traces its origins to 1919, when Francesco Angelini established the pharmaceutical business that became the foundation of the family-owned group. The company’s early identity was therefore rooted in medicines rather than in the diversified portfolio associated with the modern Angelini Industries structure. During the 1960s, scientists working at Angelini developed trazodone, an antidepressant that became one of the group’s best-known scientific contributions. This history helped establish pharmaceuticals as the enduring center of the organization’s activities. Over subsequent decades, Angelini expanded beyond its original medicines base into adjacent healthcare and consumer businesses while maintaining family ownership. Since 2000, Angelini has produced Amuchina, a sanitizing solution invented by Oronzio De Nora. The product connected the group with household and institutional sanitation as well as with its established healthcare positioning. The group also developed or acquired interests in consumer health and personal care, broadening its presence beyond prescription medicines. Angelini’s international profile became more prominent as the group developed operations outside Italy. The referenced material describes offices in 21 countries and a workforce of approximately 5,800 people. In 2018, a Reputation Institute assessment placed Angelini 66th in its overall corporate-reputation ranking and second among life-sciences companies, indicating a relatively strong standing within that sector at the time. The group pursued further portfolio expansion in the 2020s. In 2020 it took ownership of ThermaCare, a transdermal analgesic patch business that Pfizer had spun off in connection with the merger of Pfizer’s consumer-health division with GlaxoSmithKline’s consumer-health operations. In January 2021, Angelini acquired Swiss biotechnology company Arvelle Therapeutics for a reported $960 million. The transaction reinforced the group’s interest in specialty pharmaceuticals and biotechnology. In 2022, the organization was rebranded as Angelini Industries. The new identity brought several business areas under a common group architecture: Angelini Pharma, Angelini Technologies, Angelini Wines & Estates, Angelini Beauty and Angelini Ventures. The rebrand presented Angelini as a diversified industrial group whose pharmaceutical and healthcare activities coexist with technology, beauty, wine and investment businesses. Angelini continues to be privately owned by the Angelini family and is identified in the reference material as being led by Sergio Marullo di Condojanni and Thea Paola Angelini. Publicly available material supplied for this entry does not provide sufficient detail to reconstruct every subsidiary, product launch, acquisition, financial result or leadership transition, so the history is limited to the documented milestones.
- 2022
Rebranded as Angelini Industries
[1]The group adopted the Angelini Industries identity and grouped its activities under five named business areas.
- 2021
Arvelle Therapeutics acquired
[1]Angelini acquired Swiss biotechnology company Arvelle Therapeutics in January for a reported $960 million.
- 2020
ThermaCare ownership acquired
[1]Angelini took ownership of ThermaCare, the transdermal analgesic patch business separated by Pfizer after its consumer-health combination with GlaxoSmithKline.
- 2018
Corporate reputation ranking
[1]Angelini ranked 66th overall and second among life-sciences companies in a Reputation Institute corporate-reputation evaluation.
- 2000
Amuchina production begins
[1]Angelini became the producer of Amuchina, a sanitizing solution invented by Oronzio De Nora.
- 1960
Trazodone developed
[1]Angelini scientists developed trazodone during the 1960s, adding a notable antidepressant discovery to the group’s pharmaceutical history.
- 1919
Pharmaceutical business established
[1]Francesco Angelini founded the pharmaceutical business that formed the basis of the later Angelini group.
Products and positioning
A family-owned, internationally operating Italian industrial group built around pharmaceuticals and healthcare, with diversified businesses in technology, beauty, wine and venture investment.
Prescription and consumer medicines
Pharmaceuticals
Pharmaceuticals are Angelini’s historical and central business area. The group’s documented pharmaceutical history includes the development of trazodone during the 1960s and the later acquisition of specialty-pharmaceutical capabilities through Arvelle Therapeutics. The supplied material does not establish a complete current list of prescription products or brands.
Antidepressant medicine · 1960
Trazodone
Trazodone is an antidepressant developed during the 1960s by scientists at Angelini. It is a historically significant pharmaceutical associated with the group’s research activities. The available reference does not specify the full present-day licensing, marketing or geographic distribution arrangements for the medicine.
Sanitizing solution · 2000
Amuchina
Amuchina is a sanitizing solution invented by Oronzio De Nora and produced by Angelini since 2000. It represents the group’s presence in sanitation and consumer-health-related products. The reference material does not provide a detailed product history or a complete description of its current market range.
Transdermal analgesic patch
ThermaCare
ThermaCare is a transdermal analgesic patch business that became part of Angelini’s portfolio in 2020. Its ownership transfer expanded the group’s consumer-health and pain-relief activities. The supplied source does not provide a complete account of the product’s markets or subsequent portfolio changes.
Technology · 2022
Angelini Technologies
Angelini Technologies is one of the business areas introduced under the Angelini Industries identity in 2022. It represents the group’s technology-related activities, although the available reference material does not identify specific products, subsidiaries or technology categories.
Beauty and personal care · 2022
Angelini Beauty
Angelini Beauty is the group’s named beauty and personal-care business area following the 2022 rebrand. It extends Angelini’s consumer-facing portfolio beyond medicines and sanitation. Specific brands, product lines and markets are not identified in the supplied reference material.
Wine · 2022
Angelini Wines & Estates
Angelini Wines & Estates is the group’s wine-related business area established within the Angelini Industries architecture. It reflects the group’s diversification into wine production and estates, but the available source does not list individual estates, labels or geographic markets.
Brand decisions
2022
Adopt Angelini Industries group identityStrategyBackground
Angelini had developed activities across pharmaceuticals, technology, wine, beauty and venture investment, creating a need for a broader group-level identity.
Action taken
The group rebranded as Angelini Industries and introduced five named business areas: Angelini Pharma, Angelini Technologies, Angelini Wines & Estates, Angelini Beauty and Angelini Ventures.
Aftermath
The rebrand established a common architecture for the diversified family-owned group. The supplied material does not describe later changes to that structure.
2021
Acquire Arvelle TherapeuticsM&ABackground
Angelini pursued an expansion of its specialty-pharmaceutical and biotechnology activities through the acquisition of a Swiss biotechnology company.
Action taken
Angelini acquired Arvelle Therapeutics in January 2021.
Aftermath
The acquisition strengthened the group’s position in specialty pharmaceuticals. The reported transaction value was $960 million.
Reported acquisition value. $960 million (January 2021)
2020
Acquire ownership of ThermaCareM&ABackground
Pfizer separated the ThermaCare transdermal analgesic patch business after the merger of its consumer-health division with GlaxoSmithKline’s consumer-health division.
Action taken
Angelini took ownership of ThermaCare.
Aftermath
The transaction expanded Angelini’s consumer-health and pain-relief portfolio. The supplied material does not document subsequent financial or operational outcomes.
Recent events
Angelini announces acquisition of Arvelle Therapeutics[2]
Reported:
Angelini said it would acquire Arvelle Therapeutics in an all-cash transaction valuing the biopharmaceutical company at up to $960 million. The deal would give Angelini Pharma exclusive commercial rights to Arvelle's epilepsy treatment cenobamate in the EU, the UK and Switzerland.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/angelini · Editorial policy · How profiles are compiled